Assembly Biosciences, Inc. (NASDAQ:ASMB) Receives $45.60 Consensus PT from Brokerages

Assembly Biosciences, Inc. (NASDAQ:ASMB) has been assigned an average recommendation of “Moderate Buy” from the eight research firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $45.60.

A number of equities research analysts recently weighed in on the stock. Zacks Research raised shares of Assembly Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 20th. HC Wainwright reissued a “buy” rating and issued a $50.00 price target on shares of Assembly Biosciences in a research note on Tuesday, August 18th. Guggenheim reissued a “buy” rating and issued a $43.00 price target on shares of Assembly Biosciences in a research note on Thursday, May 28th. UBS Group initiated coverage on shares of Assembly Biosciences in a report on Tuesday, September 1st. They issued a “buy” rating and a $52.00 price target on the stock. Finally, Mizuho set a $53.00 price objective on shares of Assembly Biosciences in a research report on Tuesday, September 1st.

Institutional Investors Weigh In On Assembly Biosciences

A number of large investors have recently added to or reduced their stakes in the company. Seven Fleet Capital Management LP increased its position in shares of Assembly Biosciences by 671.5% during the 2nd quarter. Seven Fleet Capital Management LP now owns 433,147 shares of the biopharmaceutical company’s stock valued at $11,903,000 after purchasing an additional 377,000 shares during the last quarter. Stempoint Capital LP lifted its position in Assembly Biosciences by 18.3% in the 1st quarter. Stempoint Capital LP now owns 185,435 shares of the biopharmaceutical company’s stock worth $5,146,000 after buying an additional 28,707 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in Assembly Biosciences in the 2nd quarter worth approximately $660,000. Eversept Partners LP bought a new stake in Assembly Biosciences in the 4th quarter worth approximately $5,431,000. Finally, 683 Capital Management LLC purchased a new stake in Assembly Biosciences in the fourth quarter worth approximately $948,000. Hedge funds and other institutional investors own 19.92% of the company’s stock.

Assembly Biosciences Stock Performance

NASDAQ:ASMB opened at $26.11 on Wednesday. Assembly Biosciences has a 52-week low of $20.23 and a 52-week high of $39.71. The stock has a fifty day moving average of $29.72 and a 200 day moving average of $28.35. The firm has a market capitalization of $531.60 million, a price-to-earnings ratio of 25.60 and a beta of 1.13.

Assembly Biosciences (NASDAQ:ASMB) last announced its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.52. The business had revenue of $13.37 million for the quarter, compared to analyst estimates of $8.60 million. Assembly Biosciences had a negative return on equity of 0.02% and a negative net margin of 0.06%. Equities analysts forecast that Assembly Biosciences will post 2.28 earnings per share for the current fiscal year.

About Assembly Biosciences

Assembly Biosciences, Inc is a clinical-stage biotechnology company developing oral therapies for serious viral infections. Its research programs have focused primarily on chronic hepatitis B virus (HBV) infection and herpesvirus diseases, with the goal of addressing areas where existing treatments may not provide a functional cure or durable disease control.

The company’s pipeline includes investigational HBV capsid assembly modulators, including ABI-4334, designed to interfere with key stages of the HBV lifecycle.